NCT02975037View on ClinicalTrials.gov

Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

March 4, 2017

Study Completion Date

June 23, 2017

Conditions
Healthy
Interventions
DRUG

Sildenafil

sildenafil 25 mg PO

DRUG

Clarithromycin

clarithromycin 250 mg PO

DRUG

Itraconazole

itraconazole 100 mg PO

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02975037 - Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors | Biotech Hunter | Biotech Hunter